At a Glance
Quickcomparison
Dose Range
Pentadecapeptide (BPC Analog)
250 mcg–1000 mcg mcg
BPC-157
250–500 mcg
Frequency
Once daily
Administration
Intramuscular injection
Subcutaneous injection
Cycle Length
Ongoing/indefinite
4-6 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Moderate human trials (Phase 1-2)
Strong preclinical (extensive animal studies)
Efficacy
Benefitratings
Tissue Repair & Recovery
Angiogenesis (Blood Vessel Formation)
Anti-Inflammatory Effects
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compoundspecifications
Molecular Formula
C62H98N16O22
Molecular Weight
1419.5 g/mol
Half-Life
Not precisely established in humans; likely hours to days depending on tissue depot
Bioavailability
Significantly improved with parenteral administration (injection); poor with oral route
CAS Number
Not assigned (research compound)
1419.53 g/mol
4-6 hours
~100% (subcutaneous)
137525-51-0
Protocols
Dosingtiers
starting
250 mcg
1-2 weeks
A common starting amount in research practice, often injected near the injured area. As a BPC-157 analog it follows the same documented practice; no human trials exist, so doses come from animal studies (reference ~10 mcg/kg) and community practice [1][2].
standard
200-500 mcg
Once or twice daily
Commonly used range for tissue and tendon recovery in research practice, mirroring BPC-157 dosing [1][3].
advanced
500 mcg
Twice daily
6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Commonly used range for tissue and tendon recovery in research practice [1][3].
Applications
Bestsuited for
Recovering from sports injuries or muscle strains
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on recovering from sports injuries or muscle strains. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting post-surgery tissue repair
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on supporting post-surgery tissue repair. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Accelerating tendon and ligament healing
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on accelerating tendon and ligament healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving overall recovery speed
Pentadecapeptide (BPC Analog) is particularly well-suited for individuals focused on improving overall recovery speed. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Sideeffects
Common
Injection site irritation
Headache
Nausea
Uncommon
Dizziness
Mood or anxiety changes
Serious
Allergic reaction
Injection site redness
Mild nausea
Fatigue
Hot/cold sensations
Research Status
Safety& evidence
FDA Status
Research compound
Safety Overview
BPC-157 analogs show favorable safety in animal toxicity studies with LD50 >1000 mg/kg (oral, rats). No serious adverse events in limited clinical case reports; mild local injection site effects observed. Gastroprotective mechanism suggests low systemic toxicity; rapid hepatic metabolism limits systemic exposure. Preclinical studies show no mutagenicity, carcinogenicity, or teratogenicity; reproductive safety appears favorable.
Contraindications
xActive cancer or high cancer risk
xPregnancy or breastfeeding
xKnown hypersensitivity to peptides
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
xPregnancy
xBreastfeeding
xActive cancer
xHistory of cancer
Decision Guide
Which isright for you?
Choose Pentadecapeptide (BPC Analog) if...
Recovering from sports injuries or muscle strains
Supporting post-surgery tissue repair
Accelerating tendon and ligament healing
Improving overall recovery speed
Choose BPC-157 if...
Injury recovery
Post-surgery healing
Chronic pain management
Gut health